Company / R&D Expense
Pacira BioSciences, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$117.3M
FY2025
5-year range
$72.1M / $117.3M
FY2021-FY2025
Trend
+43.8%
vs FY2024
Sector context
#128 of 210
Health Care
What the data says
At $117M, Pacira BioSciences, Inc.'s r&d expense ranks #128 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $29M in FY2017 to $117M in FY2025.
Based on SEC 10-K filings.
$117M in FY2025 with a 5-year CAGR of +16.1%.
Improved from $76M to $117M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +11.4%
- 5-Year CAGR
- +16.1%
- 10-Year CAGR
- -
Sector benchmark
#128 of 210 in Health CareTop 61% of 210This company $117.3M Sector average $644.0M
▼
-81.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.1%, indicating consistent growth.
- In FY2025, r&d expense increased 43.8% year-over-year.
- Ranks #128 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $117.3M | +43.8% |
| FY2024 | $81.6M | +7.0% |
| FY2023 | $76.3M | -10.1% |
| FY2022 | $84.8M | +17.6% |
| FY2021 | $72.1M | +29.5% |
| FY2020 | $55.7M | -2.8% |
| FY2019 | $57.3M | +25.4% |
| FY2018 | $45.7M | +59.4% |
| FY2017 | $28.7M | -37.3% |
| FY2016 | $45.7M | +59.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026